Ignite Creation Date:
2024-05-05 @ 4:58 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00356525
Status:
TERMINATED
Last Update Posted:
2010-08-17
First Post:
2006-07-24
Brief Title:
Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer NSCLC After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Phase II Randomized Open-Label Trial of Biweekly Pemetrexed Plus Gemcitabine vs Pemetrexed or Pemetrexed Plus Carboplatin in Relapsed Non Small Cell Lung Cancer After Neoadjuvant or Adjuvant Chemotherapy
Status:
TERMINATED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Stopped early due to low enrollment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to help answer
Whether pemetrexed gemcitabine andor carboplatin can shrink tumors or make tumors disappear in patients with relapsed lung cancer lung cancer that has come back after surgical removal and chemotherapy and to determine how long this will last
Whether pemetrexed gemcitabine andor carboplatin can help patients with relapsed lung cancer live longer
Whether pemetrexed gemcitabine andor carboplatin can shrink tumors or make tumors disappear in patients with relapsed lung cancer lung cancer that has come back after surgical removal and chemotherapy and to determine how long this will last
Whether pemetrexed gemcitabine andor carboplatin can help patients with relapsed lung cancer live longer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H3E-US-S082 | OTHER | Eli Lilly and Company | None |